Join CTTC | Print Page | Contact Us | Sign In
Upcoming Webinars

CTTC presents a webinar series available for both CTTC members and non-members, on a variety of topics related to the field of hematopoietic stem cell transplant and cell therapy. 

CTTC Member & Non-Member Pricing: FREE access to all webinars in the 2020 Webinar Series


To promote the CTTC 2020 Webinar Series in your centre, please download the CTTC 2020 Webinar Series poster.
 

The University of British Columbia Division of Continuing Professional Development (UBC CPD) is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME) to provide study credits for continuing medical education for physicians.  This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and has been approved by UBC CPD for up to 8.0 MOC Section 1 Group Learning credits.Each physician should claim only those credits he/she actually spent in the activity.


 

2020 Webinar Series

October 28, 2020
12:00pm PT/3:00pm ET
CME Credit Hours: 1.0
 

The Role of Autologous Stem Cell Transplant in Myeloma in 2020

Donna Reece, MD (Princess Margaret Hospital, Toronto, ON)

Speaker Biography:
Dr. Reece is Professor of Medicine at the University of Toronto and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at the Princess Margaret Cancer Centre/University Health Network. She is currently Co-Chair of the Multiple Myeloma Disease Site Group of the CCTG (Canadian Cancer Trials Group) and participates in the MMRC (Multiple Myeloma Research Consortium). She also serves on the Board of Directors of the International Myeloma Society, Myeloma Canada and the Myeloma Canada Research Network (MCRN). For 10 years, she was Co-Chair of the Multiple Myeloma Working Committee of the International Center for Blood and Marrow Transplant Research (CIBMTR). In 2009, she was awarded the Molly and David Bloom Chair in Multiple Myeloma Research and since 2016 has spearheaded the development of the MCRN in her role as the Chief Medical Officer of this organization, which is a collaborative network focused on multicentre clinical trials and a national database. She has published numerous papers in the area of stem cell transplantation and plasma cell disorders.

Learning Objectives:
1.     To understand the role of ASCT in the era of newer anti-myeloma treatments, including immunotherapy.
2.     To discuss the use of post-ASCT treatment, with a focus on options for maintenance therapy.
3.     To review strategies for improving the outcome of ASCT in high-risk myeloma patients.

 

This webinar is sponsored by an unrestricted educational grant from 


November 4, 2020
9:00am PT/12:00pm ET


Management of CMV: What’s New, What’s Innovative, What Does the Future Hold?


Alissa Wright
MD (Vancouver General Hospital, St Paul’s Hospital, Vancouver Coastal Health, Vancouver, BC)
Jean-Sébastien DelisleMD, FRCPC, PhD (Hôpital Maisonneuve-Rosemont, Montreal, Québec)
Donald VinhMD, FRCPC, FACP (Department of Medicine, Faculty of Medicine, McGill University, Montreal, Québec) 

Learning Objectives: 
1. Appraise new evidence for CMV prophylaxis in the post-transplant setting
2. Review human models of anti-CMV immunity to gain insight into immunopathogenesis of disease as a framework for immunotherapy
3. Understand the current and future role of adoptive immunotherapy in the prevention and treatment of CMV post-transplant

 

 

This webinar is sponsored by  


 

November 18, 2020
9:00am PT/12:00pm ET

CAR-T in Diffuse Large B-Cell Lymphoma: Who and When?

Isabelle Fleury, MD (Hôpital Maisonneuve-Rosemont, Montreal, QC)


Speaker Biography:
Dr. Isabelle Fleury is a hemato-oncologist working at Maisonneuve-Rosemont Hospital since 2014. She did her training at University of Montreal where she also completed a master degree in pharmacogenetics applied to acute lymphoblastic leukemia. Her fellowship was dedicated to clinical research in lymphoma at Hôpital Saint-Louis in Paris. She is an assistant professor at University of Montreal and is the head of the lymphoma clinic at Maisonneuve-Rosemont Hospital. Her main interest is improving the care of patients with lymphoma. She contributes to clinical research in lymphoma through participating in phase 1 to 3 trials. She is the instigator of the C3i Lymphoma Registry collecting clinical and bioclinical data to better understand lymphoma. She participates in clinical trials of immune effector cells and is actively involved in the implementation of CAR-T in clinical practice in Quebec.
 
Learning Objectives:

After completing this program, participants will be able to:

  1. Review current data on available CAR-T for large B-cell lymphoma
  2. Identify appropriate candidates for CAR-T
  3. Mangement of patients with lymphoma after CAR-T


This webinar is sponsored by  


November 25, 2020
12:00pm PT/3:00pm ET
CME Credit Hours: 1.0

Engineered Immune Effector Cells for Hematologic Malignancies

Kevin Hay, MD, MSc, FRCPC (BC Cancer Agency, Vancouver, BC)
 
Learning Objectives:
TBA


This webinar is sponsored by an unrestricted educational grant from 


 

This website is sponsored by an 
unrestricted educational grant from: